Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology

Patent ExpiryapprovedNamodenosonPositive

AI Analysis

Summary

Can-Fite BioPharma has secured a Japanese patent allowance for Namodenoson's anti-obesity technology, strengthening its intellectual property position in the Japanese market.

Outcome Details

Japanese patent allowance for anti-obesity technology

Importance:5/10

Sentiment:

0.60

patentJapanintellectual propertyanti-obesityNamodenoson

Related Companies

$CANF

Read the original article

Published by yahoo_finance on June 26, 2026 11:00 AM

Read Original